Development and validation of determination of genotoxic impurity Bromoethane in Vigabatrin drug substance using head space gas chromatographic method [HS-GC]

被引:6
作者
Narapereddy, Krishna Prasad [1 ]
Alladi, Devi Sravanthi [2 ]
机构
[1] Reckitt Benckiser LLC, Res & Dev R&D, 2002 S 5070 W, Salt Lake City, UT 84104 USA
[2] Acharya Nagarjuna Univ, Dept Chem, Guntur, AP, India
关键词
Validation; Bromoethane; Genotoxic impurity; Vigabatrin drug substance; ICH guidelines; EPILEPSY; BROMIDE;
D O I
10.3897/pharmacia.70.e97339
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A specific HS-GC method has been developed, optimized, and validated for the determination of genotoxic impurity Bromoethane in Vigabatrin (VGB) drug substance. Chromatographic separation of genotoxic Bromoethane impurity was achieved on DB-1 column (30 m x 0.53 mm, 5.0 mu m), consists of 100% dimethyl polysiloxane as stationary phase and passing nitrogen carrier gas. The perfor-mance of the method was assessed by evaluating the specificity, linearity, sensitivity, precision, and accuracy experiments. The estab-lished limit of detection and limit of quantification values for the genotoxic impurity was in the range of 3.57-10.80 mu g/mL. The correla-tion coefficient value of the linearity experiment was 0.9880. The average recoveries for the accuracy were in the range of 95.3-106.8%. The results proved that the method is suitable for the determination of Bromoethane content in Vigabatrin.
引用
收藏
页码:203 / 207
页数:5
相关论文
共 22 条
[1]   Development of a headspace gas chromatographic test for the quantification of 1-and 2-bromopropane in human urine [J].
B'Hymer, C ;
Cheever, KL .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2005, 814 (01) :185-189
[2]   Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre randomised double-blind study [J].
Chadwick, D .
LANCET, 1999, 354 (9172) :13-19
[3]  
European Medicines Evaluation Agency, 2006, CPMPSWP519902 CHMP
[4]  
Genotoxic and carcinogenic impurities in drug substances and Products, 2008, GEN CARC IMP DRUG SU
[5]   VIGABATRIN - A REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES, AND THERAPEUTIC POTENTIAL IN EPILEPSY AND DISORDERS OF MOTOR CONTROL [J].
GRANT, SM ;
HEEL, RC .
DRUGS, 1991, 41 (06) :889-926
[6]  
Gu YL, 2014, ZHONG GUO WEISHENG J, V24, P1089
[7]   Enhancement of electron-capture detection of methyl bromide in air by iodination [J].
Hughes, RA ;
Knighton, WB ;
Grimsrud, EP .
JOURNAL OF CHROMATOGRAPHY A, 1999, 852 (02) :535-543
[8]  
ICH, 2006, IMPURITIES NEW DRUG
[9]  
International Conference for Harmonization, 2005, ICH Harmonized Tripartite Guideline, Validation of analytical procedures: text and methodology, Q2(R1), P1, DOI DOI 10.1007/S11095-007-9511-1
[10]   Pharmacokinetics of the S(+) and R(-) enantiomers of vigabatrin during chronic dosing in a patient with renal failure [J].
JacqzAigrain, E ;
Guilionneau, M ;
Rey, E ;
Macher, MA ;
Montes, C ;
Chiron, C ;
Loirat, C .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 44 (02) :183-185